Top

Journal of Clinical Immunology

Published in:

01-04-2013 | Brief Communication

Increased Plasma Interleukin-32 Expression in Patients with Neuromyelitis Optica

Authors: Honghao Wang, Kai Wang, Conghui Wang, Fangcheng Xu, Wei Qiu, Xueqiang Hu

Published in: Journal of Clinical Immunology | Issue 3/2013

Abstract

Purpose

Neuromyelitis optica (NMO) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). The pathogenesis of NMO remains unclear. IL-32 is emerging as a critical molecule in the pathophysiology of immune-mediated chronic inflammatory diseases. Whether IL-32 levels are elevated in NMO patients is unclear. We aimed to determine whether IL-32 levels are elevated in NMO patients and explore its relationship with IL-6, IL-17, and Expanded Disability Status Scale (EDSS) scores.

Methods

Plasma IL-32α, IL-6 and IL-17A were measured by enzyme-linked immunosorbent assay in NMO (n = 26), MS (n = 23) and 22 healthy controls.

Results

We found IL-32α levels were higher in NMO patients compared with MS (p = 0.020) and healthy controls (p = 0.00001). IL-32α levels were increased in MS patients compared with controls (p = 0.009). IL-32α positively correlated with IL-6 and IL-17A levels and EDSS scores in NMO patients.

Conclusions

In summary, plasma IL-32α levels are associated with inflammatory responses in NMO patients.

Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Na-kashima I, Weinshenker BG. A serum auto-antibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106–12.PubMedCrossRef

Wang H, Wang K, Zhong X, Qiu W, Dai Y, Wu A, Hu X. Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse. J Clin Immunol. 2012;32:1007–11.PubMedCrossRef

Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012;11:535–44.PubMedCrossRef

Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, Trebst C, Weinshenker B, Wingerchuk D, Parisi JE, Lassmann H. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002;12:51450–1461.

Barnett MH, Sutton I. Neuromyelitis optica: not a multiple sclerosis variant. Curr Opin Neurol. 2012;25:215–20.PubMedCrossRef

Turner-Brannen E, Choi KY, Arsenault R, El-Gabalawy H, Napper S, Mookherjee N. Inflammatory cytokines IL-32 and IL-17 have common signaling intermediates despite differential dependence on TNF-receptor 1. J Immunol. 2011;186:7127–35.PubMedCrossRef

Steinman L, Conlon P. Antigen specific immunotherapy of multiple sclerosis. J Clin Immunol. 2001;21:93–8.PubMedCrossRef

Park YE, Kim GT, Lee SG, Park SH, Baek SH, Kim SI, Kim JI, Jin HS. IL-32 aggravates synovial inflammation and bone destruction and increases synovial natural killer cells in experimental arthritis models. Rheumatol Int. 2012;PubMed PMID: 22527134.

Meyer N, Christoph J, Makrinioti H, Indermitte P, Rhyner C, Soyka M, Eiwegger T, Chalubinski M, Wanke K, Fujita H, Wawrzyniak P, Bürgler S, Zhang S, Akdis M, Menz G, Akdis C. Inhibition of angiogenesis by IL-32: possible role in asthma. J Allergy Clin Immunol. 2012;129:964–73.PubMedCrossRef

10.

Na SJ, So SH, Lee KO, Choi YC. Elevated serum level of interleukin-32α in the patients with myasthenia gravis. J Neurol. 2011;258:1865–70.PubMedCrossRef

11.

Heinhuis B, Netea MG, van den Berg WB, Dinarello CA, Joosten LA. Interleukin-32: A predominantly intracellular proinflammatory mediator that controls cell activation and cell death. Cytokine. 2012;PubMed PMID: 22878344.

12.

Jung MY, Son MH, Kim SH, Cho D, Kim TS. IL-32gamma induces the maturation of dendritic cells with Th1- and Th17-polarizing ability through enhanced IL-12 and IL-6 production. J Immunol. 2011;186:6848–59.PubMedCrossRef

13.

Noh J, Noh G. Allergen-specific. Responses of CD19high and CD19low B Cells in Non-IgE mediated food allergy of late eczematous reactions in atopic dermatitis: presence of IL-17- and IL-32-producing regulatory B cells (Br17 & Br32). Inflamm Allergy Drug Targets. 2012;11:320–9.PubMedCrossRef

14.

Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485–9.PubMedCrossRef

15.

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292–302.PubMedCrossRef

16.

Heinhuis B, Koenders MI, van Riel PL, van de Loo FA, Dinarello CA, Netea MG, van den Berg WB, Joosten LA. Tumour necrosis factor alpha-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies an inflammatory cascade. Ann Rheum Dis. 2011;70:660–7.PubMedCrossRef

17.

Xu Q, Pan X, Shu X, Cao H, Li X, Zhang K, Lu J, Zou Y, Li X, Liu H, Zhang Y, Yang D, Ning Q, Shen G, Li G. Increased interleukin-32 expression in chronic hepatitis B virus-infected liver. J Infect. 2012;65:336–42.PubMedCrossRef

18.

Heinhuis B, Koenders MI, van den Berg WB, Netea MG, Dinarello CA, Joosten LA. Interleukin 32 (IL-32) contains a typical α-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1. J Biol Chem. 2012;287:5733–43.PubMedCrossRef

19.

Conti P, Youinou P, Theoharides TC. Modulation of autoimmunity by the latest interleukins (with special emphasis on IL-32). Autoimmun Rev. 2007;6:131–7.PubMedCrossRef

20.

Netea MG, Azam T, Ferwerda G, Girardin SE, Walsh M, Park JS, Abraham E, Kim JM, Yoon DY, Dinarello CA, Kim SH. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci U S A. 2005;102:16309–14.PubMedCrossRef

21.

Wang H, Wang K, Zhong X, Dai Y, Qiu W, Wu A, Hu X. Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in neuromyelitis optica. Neuroimmunomodulation. 2012;19:304–8.PubMedCrossRef

22.

Chihara N, Aranami T, Sato W, Miyazaki Y, Miyake S, Okamoto T, Ogawa M, Toda T, Yamamura T. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A. 2011;108:3701–6.PubMedCrossRef

23.

Furlan R, Martino G, Galbiati F, Poliani PL, Smiroldo S, Bergami A, Desina G, Comi G, Flavell R, Su MS, Adorini L. Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J Immunol. 1999;163:2403–9.PubMed

24.

Zepp J, Wu L, Li X. IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease. Trends Immunol. 2011;32:232–9.PubMedCrossRef

25.

Misu T, Takahashi T, Nakashima I, Fujihara K. Biomarkers in neuromyelitis optica. Brain Nerve. 2012;64:525–35.PubMed

26.

Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, Nelson PA, Stroud RM, Cree BA, Zamvil SS. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol. 2012;72:53–64.PubMedCrossRef

27.

Wang H, Dai Y, Qiu W, Lu Z, Peng F, Wang Y, Bao J, Li Y, Hu X. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J Clin Neurosci. 2011;18:1313–7.PubMedCrossRef

28.

Li Y, Wang H, Long Y, Lu Z, Hu X. Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis. J Neuroimmunol. 2011;234:155–60.PubMedCrossRef

Title: Increased Plasma Interleukin-32 Expression in Patients with Neuromyelitis Optica
Authors: Honghao Wang
Kai Wang
Conghui Wang
Fangcheng Xu
Wei Qiu
Xueqiang Hu
Publication date: 01-04-2013
Publisher: Springer US
Published in: Journal of Clinical Immunology / Issue 3/2013
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-012-9837-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2013

Comprehensive Report of Primary Immunodeficiency Disorders from a Tertiary Care Center in India

Inflammatory Bowel Disease and T cell Lymphopenia in G6PC3 Deficiency

MiR-320a is Downregulated in Patients with Myasthenia Gravis and Modulates Inflammatory Cytokines Production by Targeting Mitogen-activated Protein Kinase 1

N-acetylcysteine Administration is Associated with Reduced Activation of NF-kB and Preserves Lung Dendritic Cells Function in a Zymosan-Induced Generalized Inflammation Model

The Influence of Recombinant Human Erythropoietin on Apoptosis and Cytokine Production of CD4+ lymphocytes from Hemodialyzed Patients

Newborn Screening for SCID Identifies Patients with Ataxia Telangiectasia

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials